UPEXI, INC. - 10-Q Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 2024, and the six months ended on that date. UPEXI, Inc. (UPXI) is a Nevada corporation operating as a smaller reporting company and emerging growth company. The company has undergone a significant strategic pivot, divesting its recommerce business units (E-Core, VitaMedica, and Interactive Offers) to focus on the development, production, and distribution of branded consumer products, including pet products and health/wellness items. Operations are consolidated in Florida following the closure of Nevada facilities.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2024 | Six Months Ended Dec 31, 2024 | As of Dec 31, 2024 |
|---|---|---|---|
| Revenue | $4,005,492 | $8,362,007 | - |
| Gross Profit | $2,974,106 | $5,904,174 | - |
| Gross Margin | 74.3% | 70.6% | - |
| Net Loss (Continuing Ops) | $(1,301,310) | $(2,926,887) | - |
| Net Loss (Total) | $(1,301,310) | $(2,926,887) | - |
| Cash and Equivalents | - | - | $406,347 |
| Working Capital | - | - | $(4,507,208) |
| Total Debt (Current + Long Term) | - | - | $8,057,565 |
| Accumulated Deficit | - | - | $(49,786,500) |
Note: Discontinued operations (E-Core, VitaMedica, Interactive Offers) generated income in the prior year but had no activity in the current period.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 46% ($3.46M) for the three months and 47% ($7.38M) for the six months compared to the prior year. This is primarily due to the strategic exit from the recommerce business (E-Core and VitaMedica) and a temporary decline in branded product sales during facility consolidation.
- Margin Expansion: Despite lower revenue, gross profit margins improved significantly to 74% (Q3) and 71% (YTD) from 61% and 64% in the prior year, reflecting the shift to higher-margin branded products.
- Expense Reduction: Operating expenses decreased substantially. Sales and marketing dropped 36% (Q3) and 40% (YTD). Distribution costs fell 49% (Q3) and 41% (YTD) due to the elimination of recommerce logistics. Amortization of intangible assets dropped 97% due to prior-year impairments.
- Asset Sales: The company sold its corporate building for $4.3M and collected $2M from the sale of E-Core, providing significant investing cash inflows ($5.84M for the six months).
- Debt Restructuring: The company repaid a $2.63M mortgage on the sold building and restructured various notes payable, including a related-party loan with the CEO.
Outlook, Risks, and Contingencies
- Going Concern Warning: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for the next 12 months. This is due to an accumulated deficit of $49.8M, recurring net losses, and negative operating cash flows. The company relies on raising additional capital or reducing expenditures to survive.
- Capital Needs: The company expects to require additional funding to support operations and is actively pursuing equity or debt financing. Recent related-party advances ($100k in June, $400k post-period) highlight liquidity constraints.
- Legal Proceedings: The company is involved in active arbitration with Get Fit Fast Supplements, LLC regarding the acquisition of Cygnet Online, LLC. Claims include breach of contract and fraud.
- Internal Controls: The company identified material weaknesses in internal controls, specifically inadequate segregation of duties and lack of multiple levels of supervision. Remediation is planned but not yet complete.
- Regulatory Risks: The company faces uncertainty regarding federal and state regulations on hemp and cannabinoids, which could impact product distribution.
- Reverse Stock Split: A 1-for-20 reverse stock split was effective October 3, 2024, to regain Nasdaq compliance. The company is litigating to prevent dilution from fractional share rounding disputes.
Investor Verification Checklist
- Liquidity Runway: Verify the status of the $406k cash balance against the $8M+ debt obligations and monthly burn rate to assess immediate solvency risk.
- Financing Progress: Confirm if the company has secured the "additional capital" mentioned in the going concern disclosure to fund operations for the next 12 months.
- Discontinued Operations: Ensure financial comparisons exclude the high-revenue E-Core and VitaMedica units to accurately assess the performance of the remaining branded product business.
- Related Party Transactions: Review the terms of the lease with the CEO's entity (MFA 2510 Merchant LLC) and the $500k related-party note for fairness and repayment terms.
- Legal Exposure: Monitor the outcome of the arbitration with Get Fit Fast Supplements, as damages could materially impact the balance sheet.
- Inventory Valuation: Scrutinize the $2.2M inventory balance and the $605k reserve, given the company's history of writing down obsolete stock.